At the news
? NEUTRALIMPACT 5/10 8-K filed Nov 4, 2026 at 16:01 ET
Xencor reported Q3 2026 revenue of $116.5M (vs consensus $63.0M) and GAAP diluted EPS of $0.50 (vs consensus $-0.34), driven by milestone and royalty revenue from partners. The beat was largely non-operational, reflecting a $25M Astellas milestone and $52.5M Alexion settlement payment, while R&D spending rose to $84.3M. Pipeline highlights include XmAb819 45.5% confirmed ORR at 400 mcg/kg in ccRCC and plans to initiate a Phase 3 study by end of 2027.
- Q3 2026 revenue $116.5M vs $21.0M YoY, primarily from royalties and milestones
- GAAP diluted EPS $0.50 vs net loss of $(0.08) in Q3 2025
- Consensus was EPS $-0.34 and revenue $63.0M; EPS beat by $0.84, revenue beat by $53.5M
- R&D expenses $84.3M, up from $54.4M YoY, driven by higher program costs
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access